vimarsana.com

Page 45 - Eckert Ziegler News Today : Breaking News, Live Updates & Top Stories | Vimarsana

Eckert & Ziegler s GalliaPharm distributed by Curium in France

Eckert & Ziegler s GalliaPharm distributed by Curium in France Berlin, Germany and Paris, France, March 01, 2021 (GLOBE NEWSWIRE) Eckert & Ziegler Radiopharma GmbH and Curium PET France have decided to reinforce their existing long term partnership by extending their agreement for the distribution of Galliapharm generators in France, Curium being the partner of choice given the national coverage of its PET network in France . Achieving greater market penetration for our core product GalliaPharm is the focus of our sales strategy. With its established network in France, Curium is thus perfectly qualified to be our partner, Dr. Harald Hasselmann, member of the Executive Board of Eckert & Ziegler AG and responsible for the Medical segment, explained. In the coming years, Gallium-68 based diagnostics will become even more prevalent than today. Eckert & Ziegler is ideally equipped to serve these market needs. Since currently several clinical studies are conducted worldwide wi

The Worldwide Intraoperative Radiation Therapy Industry is Expected to Reach $66 Million by 2025

The Worldwide Intraoperative Radiation Therapy Industry is Expected to Reach $66 Million by 2025 News provided by Share this article Share this article ResearchAndMarkets.com s offering. The global intraoperative radiation therapy market is projected to reach USD 66 million by 2025 from USD 48 million in 2020, at a CAGR of 6.4% during the forecast period. The rising incidence of cancer, technological advancements, and advantages offered by IORT over conventional radiotherapy are the major factors driving the growth of the global intraoperative radiation therapy market. Additionally, growing clinical trials exploring the use of IORT for various cancer applications are expected to offer lucrative growth opportunities to market players. However, the complex nature of technology coupled with a shortage of trained personnel and preference of conventional radiotherapy over IORT by physicians owing to reimbursement coverage are the major factors that are expected to restrain the gro

Eckert & Ziegler s GalliaPharm® distributed by Curium in France

Eckert & Ziegler s GalliaPharm® distributed by Curium in France
globenewswire.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from globenewswire.com Daily Mail and Mail on Sunday newspapers.

Investegate |Curium Announcements | Curium: Eckert & Ziegler s GalliaPharm® distributed by Curium in France

Investegate |Curium Announcements | Curium: Eckert & Ziegler s GalliaPharm® distributed by Curium in France
investegate.co.uk - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from investegate.co.uk Daily Mail and Mail on Sunday newspapers.

Lung Cancer Screening Software Market Size 2021| Top Companies, Trends, Growth Factors Details for Business Development and Forecast to 2027 – KSU

16 Lung Cancer Screening Software Market research is an intelligence report with meticulous efforts undertaken to study the right and valuable information published by Data Bridge Market Research. Lung Cancer Screening Software market research report provides clients with the information on their business scenario with which they can build business strategies, market trends along with the drivers, restraints, challenges, and opportunities to thrive in the market. The report is a helpful resource which provides present as well as upcoming technical and financial details of the industry forecast to 2027. All the studies conducted to generate this report are based on large group sizes and that to at the global market. The Lung Cancer Screening Software market analysis report also contains detailed profiles of market’s major manufacturers and importers who are leading the market. The research process involved the study of various factors affecting the industry, including market envi

© 2025 Vimarsana

vimarsana © 2020. All Rights Reserved.